Objective: The significance of detecting herpes simplex virus (HSV) DNA in the cerebrospinal fluid (CSF) of infants with HSV encephalitis after receipt of prolonged therapy with high-dose (60 mg kg À1 day
Introduction
Neonatal herpes simplex virus (HSV) infection occurs in B1 in 1250 to 20 000 neonates per year in the United States 1,2 with approximately 30% having encephalitis. 3 Although acyclovir therapy has reduced significantly the mortality in infants with herpes encephalitis, central nervous system (CNS) infection with HSV continues to be associated with abnormal neurodevelopmental outcome in the majority of survivors. 4 Traditional risk factors that contribute to increased morbidity in these infants include the presence of seizures, duration of illness (less than 2 or greater than 8 days) before the initiation of therapy and infection with HSV-II virus. 5, 6 Polymerase chain reaction (PCR) for HSV DNA performed on cerebrospinal fluid (CSF) is the best available method for diagnosis of HSV CNS infection. 7, 8 The occurrence of a positive CSF HSV DNA PCR after receipt of prolonged therapy with high-dose (60 mg kg À1 per day) acyclovir has not been reported in detail and its significance remains unknown. For this reason, we describe four neonates with HSV encephalitis, three of whom were born in Texas and one in Chile, who had persistence of CSF HSV DNA by PCR after 14 to 21 days of high-dose acyclovir therapy. This report also describes the adverse outcomes that these infants experienced, and it highlights the need for prospective studies to document how often HSV DNA persists in CSF of infected infants and understand its prognostic significance.
Patients

Case 1
A 2860-gram female infant was delivered vaginally at 36 weeks of gestation to a 29-year-old gravida 4 , para 3003 Caucasian woman. Prenatal serologic tests revealed an absence of antibodies to the human immunodeficiency virus, a nonreactive rapid plasma reagin test, negative hepatitis B surface antigen and a negative screening culture for group B streptococcus. There was no history of genital HSV infection. Rupture of fetal membranes occurred 24 h before delivery, and a scalp electrode was used for fetal heart rate monitoring.
The infant was well until 15 days of age when she developed focal seizures. She was hospitalized at 18 days of age at Children's Medical Center Dallas (TX, USA) for persistent seizures and apneic episodes. The infant was afebrile and physical examination was significant for a small vesicle on the left inguinal area and hypertonicity. There was no hepatosplenomegaly or petechiae, and liver function tests, bilirubin concentration and complete blood cell count were normal (Table 1) . HSV-2 DNA PCR (Children's Medical Center Dallas) performed on the initial CSF specimen and blood was positive (Table 2) .
Acyclovir was provided at a dose of 40 mg kg À1 per day intravenously for 4 days and subsequently increased to 60 mg kg À1 per day. Viral cultures of the throat and vesicle did not yield HSV. Bacterial cultures of blood and CSF were sterile.
Computed tomography (CT) and magnetic resonance imaging (MRI) of the brain at presentation showed extensive cytotoxic edema involving both cerebral hemispheres. Electroencephalogram performed on hospital admission showed extensive multifocal sharp-wave activity with absence of normal background. Ophthalmologic and hearing assessments were normal.
At 40 days of age, after 18 days of high-dose acyclovir therapy, a second CSF examination revealed the persistence of HSV DNA by PCR ( Table 2 ). The infant was clinically stable without further seizure activity. Acyclovir was continued and a lumbar puncture was repeated 28 days after initiation of high-dose acyclovir. CSF HSV-2 PCR was negative, and high-dose acyclovir was discontinued at 54 days of age and after a total of 32 days. Acyclovir suppressive therapy was not provided.
The patient's serum white blood cell count and creatinine concentration remained normal during acyclovir therapy. MRI of the brain performed on day 22 of acyclovir (44 days of age) showed megacystic encephalomalacia with laminar necrosis, gliosis and cortical atrophy with parieto-occipital subdural effusions (Figure 1a) . On follow-up at 5, 11, 16 and 24 months of age, she had severe developmental delay with hypertonicity and microcephaly. She has not experienced any skin or CNS recurrences.
Case 2
A 2930-gram, 40-week female infant was delivered vaginally to a 23-year-old gravida 4 , para 3003 African-American woman. There was CSF HSV persistence in neonatal encephalitis A Mejías et al no history of genital HSV infection but she was treated for gonococcal and chlamydial infections in the first trimester of pregnancy. She lacked antibodies to human immunodeficiency virus and had nonreactive rapid plasma reagin and hepatitis B surface antigen tests. Rupture of fetal membranes occurred at delivery, and it is not known whether a fetal scalp electrode was used.
The infant was well until 28 days of age when she developed hypersommnolence, decreased oral intake, diarrhea and focal seizures. Because of persistent seizures and lethargy, she was referred to Children's Medical Center Dallas where she was hospitalized at 38 days of age. On admission the infant was afebrile, and physical examination revealed horizontal nystagmus, generalized hypertonia as well as oral candidiasis, but no hepatosplenomegaly, petechiae or skin vesicles. CSF HSV PCR (ARUP Laboratories, Salt Lake City, UT, USA) was positive but the HSV type was not performed (Table 1) . Bacterial cultures of blood and CSF, as well as viral cultures of throat, rectum and buffy coat were sterile. The infant received intravenous ampicillin, cefotaxime, acyclovir (60 mg kg À1 per day) and oral nystatin. On admission, CT scan without contrast showed subdural effusions of both frontal areas that extended over the left frontal parietal convexity, small subdural infratentorial hemorrhages, and diffusely abnormal low density of white matter and basal ganglia. Electroencephalogram did not reveal epileptiform activity. Ophthalmologic examination showed bilateral chorioretinitis.
On the 7 day of hospitalization, brain MRI showed diffuse cystic encephalomalacia of both cerebral hemispheres and bilateral subdural hygromas (Figure 1b) . At 58 days of age, on the 20th day of acyclovir therapy, a second CSF examination revealed worse CSF indices and CSF HSV PCR remained positive ( Table 2) .
The infant's hospital course was marked by progressive neurological deterioration with lethargy and minimal response to tactile stimulation, as well as intermittent fever and inappropriate production of antidiuretic hormone resulting in hyponatremia. On the third week of hospitalization, she developed opisthotonus and decerebrate posturing, and required nasogastric tube feedings. At this time, a head CT scan showed extensive cortical hemorrhage with near dissolution of the white matter. At 68 days of age, acyclovir was discontinued after 30 days of therapy without confirmation of a negative CSF HSV PCR test, as multiple attempts at performing a lumbar puncture were unsuccessful. The patient's white blood cell count and creatinine remained normal during treatment with acyclovir. Suppressive therapy with oral acyclovir was not prescribed. Follow-up evaluations at the ages of 2 and 10 months, 2, 3 and 4 years of age revealed microcephaly, spastic quadriplegia and severe developmental delay. Brain MRI at 4 years of age showed cystic encephalomalacia.
Case 3
A 2875-gram, 39-week male infant was born vaginally to a 21-year-old gravida 2 , para 1001 Caucasian woman following 1½ h of rupture of membranes. Prenatal testing was negative for human immunodeficiency virus antibodies, rapid plasma reagin and hepatitis B surface antigen tests, and group B streptococcus colonization. She had no history of genital HSV infection. Meconium-stained amniotic fluid was noted intrapartum and a scalp electrode was used to monitor the fetal heart rate. The infant had Apgar scores of 8 and 9 at 1 and 5 min, respectively. Within 2 h of birth, he developed apnea and focal seizures, and he required mechanical ventilation in the neonatal intensive care unit at Parkland Memorial Hospital (Dallas, TX, USA) ( Table 1 ). The infant was afebrile and the physical examination was significant for nasal flaring, poor peripheral perfusion, eye deviation and lip smacking. There were no vesicular skin lesions. Chest radiograph was normal. There was insufficient quantity of CSF for viral culture and HSV PCR.
The infant received initially ampicillin and gentamicin, but when the CSF indices were assessed to be abnormal at 18 h of age (Table 2) , treatment with cefotaxime and acyclovir (60 mg kg MRI of the brain performed on day 5 of acyclovir therapy showed diffuse supratentorial edema with large regions of restricted diffusion and a possible thrombus in the right transverse sinus (Figure 1c) . Electroencephalogram showed continuous seizure activity. Ophthalmologic and hearing evaluations were normal. On the 14th day of acyclovir therapy at 14 days of age, the CSF HSV-II PCR remained positive. The infant experienced more clinical seizures as well as feeding intolerance, and phosphenytoin was added to the initial anticonvulsant therapy with phenobarbital.
A cranial ultrasound performed on day 12 of acyclovir treatment showed increased echogenicity of the gray and white matter, basal ganglia and thalami, with cystic changes in the white matter of both cerebral hemispheres compatible with encephalomalacia. On the 25th day of acyclovir therapy at 25 days of age a third CSF evaluation was performed, and when the HSV PCR result was reported as negative acyclovir was discontinued after 28 days. The infant developed fulminant necrotizing enterocolitis (Bell Stage IIIA) and died 3 days later. The parents declined a postmortem examination.
Case 4
A 3710-gram, 40-week male infant was born vaginally to a 28-year-old gravida 2 , para 0010 Hispanic mother following 8 h of rupture of membranes. Prenatal serologic testing was negative for human immunodeficiency virus antibodies, as well as rapid plasma reagin and hepatitis B surface antigen tests. The mother had no history of genital HSV infection, and a fetal scalp electrode was not used intrapartum. The infant was well up to 24 days of age when he was hospitalized at Hospital Guillermo Grant Benavente in Concepcion, Chile with 1-day history of fever, irritability, poor oral intake and generalized tonic-clonic seizures. On physical examination there were no hepatosplenomegaly or skin lesions (Table 1) . CSF examination only revealed pleocytosis. CT scan of the brain was normal, and the infant received ampicillin and amikacin. Bacterial cultures of blood and CSF were sterile, but on the fourth hospital day he experienced intractable seizures and a second lumbar puncture was performed that again showed pleocytosis (Table 2) ; CSF HSV-II PCR (LightCycler HSV1/2 Detection Kit, Roche Diagnostics, performed at the Molecular Biology Laboratory, Concepcion University, Chile) was positive. A second CT scan of the brain now showed diffuse cerebral edema, and intravenous acyclovir at a dose of 60 mg kg À1 per day was initiated. At 42 days of age, an ophthalmologic examination performed on the 14th day of treatment revealed bilateral chorioretinitis and vasculitis with peripheral exudative retinopathy. At 49 days of age, on the 21st day of high-dose acyclovir treatment, a third CSF evaluation revealed a positive HSV PCR (Table 2) . At this time, his neurological examination revealed severe hypotonia with a Glasgow coma scale of 10 to 11.
At 66 days of age, on day 38 of acyclovir therapy, CSF HSV PCR was negative and acyclovir was discontinued after a total of 48 days. At this time, CT scan of the brain showed severe bilateral encephalomalacia (Figure 1d ). The infant did not receive oral suppressive acyclovir therapy and there were no known CNS recurrences. However, on follow-up at 12 months of age the patient has severe developmental delay and epilepsy.
Discussion
Since 1941, when Smith and Reames 9 first isolated HSV from the brain of a neonate with encephalitis, HSV has been a leading cause of viral CNS infections in neonates. In recent years, the diagnosis of HSV encephalitis has been greatly improved and facilitated by the development of PCR that detects HSV DNA in CSF. Its sensitivity and specificity range from 75 to 100% and 71 to 100%, respectively [10] [11] [12] but its validity is complicated by interlaboratory variability.
Lakeman and Whitley 10 of the NIAID's Collaborative Antiviral Study Group evaluated the use of PCR in 101 adult patients with biopsy-proven herpes encephalitis diagnosed between 1974 and 1987. [13] [14] [15] These patients had participated in several randomized, placebo-controlled trials of iodoxouridine, vidarabine or acyclovir, the latter provided at a dose of 30 mg kg À1 per day. During the first week of antiviral therapy, 49 (98%) of 50 CSF specimens from 39 patients were HSV DNA-positive by PCR. By the second week of therapy, HSV DNA was detected by PCR in 47% (8/17) of available CSF specimens. After 2 weeks of antiviral treatment, CSF samples from 4 (22%) of 18 subjects remained positive by PCR, 3 patients had received vidarabine and 1 was treated with acyclovir. A positive CSF HSV PCR was not associated with any abnormal clinical or laboratory findings such as level of consciousness, seizures, dysphasia, CSF indices, electroencephalogram abnormalities or Glasgow coma scale. No assessment of long-term abnormalities was performed.
The Collaborative Antiviral Study Group also performed a prospective, randomized trial of intravenous acyclovir versus vidaribine, both administered at a dose of 30 mg kg À1 per day for 10 days, in 202 neonates with HSV infection. 16 A retrospective testing of stored CSF specimens obtained from 30 of these study subjects after completion of antiviral therapy found that 14 (74%) of 18 neonates with HSV encephalitis, as well as all 5 (100%) who had disseminated disease that involved the CNS, but none of the 7 who had skin, eye or mouth disease, had a positive CSF HSV PCR. 11, 16 The majority of these CSF specimens were obtained within 10 days after antiviral therapy was discontinued, and HSV was not isolated from the 15 infants who had CSF viral cultures performed. In addition, of the 30 study subjects, 13 (87%) infants treated with vidaribine had HSV DNA detected in post-therapy CSF compared with 6 (40%) of the 15 who had received acyclovir (P ¼ 0.008). The detection of HSV DNA from post-therapy CSF was associated with moderate-to-severe neurological impairment or death in 95% of PCR-positive infants. Similarly, Kimura et al 17 reported the persistence of HSV DNA in CSF of three of five neonates with HSV disease that involved the CNS after receipt of 7 to 14 days of acyclovir at a dose of 30 mg kg À1 per day. These findings have resulted in the recommendation that patients with HSV CNS infection have a CSF HSV PCR performed before the end of antiviral therapy, and that treatment be continued until it is negative. 18 Subsequently, Kimberlin et al. 19 found that treatment of neonatal HSV infection with a higher dose of acyclovir (60 mg kg À1 per day) improved outcome. 19 Infants with CNS or disseminated HSV disease treated for 21 days had a significantly higher survival rate than similar infants from the previous Collaborative Antiviral Study Group trial that utilized acyclovir at a dose of 30 mg kg
À1
per day for 10 days. In addition, recipients of high-dose acyclovir were seven times as likely to be developmentally normal at 12 months of age as patients who received the lower dose of acyclovir.
On the basis of these findings, longer duration of therapy and a higher dose of acyclovir are recommended for treatment of neonatal HSV infection. 20 The occurrence of a positive CSF HSV PCR after 2 to 3 weeks of high-dose acyclovir therapy is known but it has not been well documented. It is possible that the persistently positive PCR reflects an initially high CSF viral load that is reflective of a greater degree of CNS injury and results in a longer time for achievement of an undetectable concentration. 21 Domingues et al. 22 found that among 16 patients with HSV-1 encephalitis who had a mean age of 37 ± 21 years, greater than 100 copies of HSV DNA per ml in CSF was associated with decreased level of consciousness, presence of lesions detected by CT scan of brain and poor neurological outcomes. Similar studies that assess the contribution of HSV viral load to neurodevelopmental outcome or antiviral response are needed in neonates. Because the HSV DNA PCR that was performed in our patients was not quantitative, we were unable to correlate viral load with abnormal neurodevelopment. In addition, the lack of CSF HSV cultures in our patients did not allow us to evaluate whether the persistently positive HSV PCR may have been due to the presence of live virus in CSF.
Persistence of HSV DNA in CSF may be secondary to acyclovir resistance, which occurs in 5% of immunocompromised patients and 0.1 to 0.6% of immunocompetent individuals. 23 Acyclovir resistance has been reported in three cases of neonatal HSV-2 infection: (1) full-term infant with infection of the larynx who recovered despite positive HSV cultures after 11 days of foscarnet therapy, 24 (2) preterm infant with congenital disseminated disease in which acyclovir resistance developed during the first 7 days of treatment (30 mg kg À1 per day) and who died despite foscarnet therapy, 25 and (3) preterm infant who developed disseminated disease 8 days after receiving 21 days of high-dose acyclovir for neurocutanous disease. This latter infant also had a positive CSF HSV PCR at 48 h after completion of the initial 21 days of acyclovir. 26 In addition, acyclovir resistance was reported in an infant who had a cutaneous HSV-2 recurrence 36 h after cessation of 6 months of acyclovir suppression. 27 These cases highlight the importance of obtaining herpes culture or performing genotypic characterization of PCR products for acyclovir resistance testing in infants who do not respond appropriately to acyclovir therapy, have frequent recurrences while on acyclovir suppressive therapy or were born to mothers who received prolonged acyclovir suppression during pregnancy. Foscarnet therapy is recommended for disease caused by an acyclovir-resistant isolate. 28 Unfortunately, determination of acyclovir resistance was not performed in our patients, although it is unlikely as three of the four patients eventually had a negative HSV CSF PCR without the addition of foscarnet.
A positive HSV CSF PCR also may represent ongoing viral replication that is not controlled satisfactorily by a neonate's immature or defective immune system. Recently, Casrouge et al. 29 reported that children who lack functional UNC-93B, an endoplasmic reticulum protein required for toll-like receptor signaling, or have mutations in toll-like receptor-3 are predisposed to develop HSV encephalitis through impaired type-I interferon responses. 30 Our patients were not tested for such defects, although this should need to be considered in the future.
In conclusion, we report the persistence of a positive HSV DNA PCR in the CSF of four neonates following 15, 18, 20 and 21 days of high-dose acyclovir. All of the infants had abnormal neuroimaging studies and subsequently experienced severe developmental delay or death. Risk factors associated with worse neurodevelopmental outcome, that is, seizures, duration of illness less than 2 days or greater than 8 days before initiation of antiviral therapy or infection with HSV-II, were present in our patients and likely contributed to the inadequate response to antiviral treatment. Prospective studies are needed to ascertain whether a persistently positive CSF HSV DNA PCR is another associated risk factor, and whether it is indicative of an initially high viral load, ongoing viral replication or antiviral resistance. Ultimately, this knowledge may improve the management of neonatal HSV encephalitis as earlier or more aggressive antiviral or immunomodulatory 31 therapy may be needed, and it may identify infants who may benefit from acyclovir suppressive therapy. 11, 32 
